Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation

Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2607-12. doi: 10.1152/ajpheart.01107.2006. Epub 2007 Jan 19.

Abstract

We have previously shown that 17beta-estradiol (E2) attenuates responses to endoluminal injury of the rat carotid artery, at least in part, by decreasing inflammatory mediator expression and neutrophil infiltration into the injured vessel, with a major effect on the neutrophil-specific chemokine cytokine-induced neutrophil chemoattractant (CINC)-2 beta. Current studies tested the hypothesis that activated rat aortic smooth muscle cells (RASMCs) express these same inflammatory mediators and induce neutrophil migration in vitro and that E2 inhibits these processes by an estrogen receptor (ER)-dependent mechanism. Quiescent RASMCs treated with E2, the ER alpha-selective agonist propyl pyrazole triol (PPT), the ER beta-selective agonist diarylpropiolnitrile (DPN), or vehicle for 24 h were stimulated with tumor necrosis factor (TNF)-alpha and processed for real-time RT-PCR, ELISA, or chemotaxis assays 6 h later. TNF-alpha stimulated and E2 attenuated mRNA expression of inflammatory mediators, including P-selectin, intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, monocyte chemoattractant protein (MCP)-1, and CINC-2 beta. DPN dose dependently attenuated TNF-alpha-induced mRNA expression of CINC-2 beta, whereas PPT had no effect. The anti-inflammatory effects of DPN and E2 were blocked by the nonselective ER-inhibitor ICI-182,780. ELISA confirmed the TNF-alpha-induced increase and E2-induced inhibition of CINC-2 beta protein secretion. TNF-alpha treatment of RASMCs produced a twofold increase in neutrophil chemotactic activity of conditioned media; E2 and DPN treatment markedly inhibited this effect. E2 inhibits activated RASMC proinflammatory mediator expression and neutrophil chemotactic activity through an ER beta-dependent mechanism.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / metabolism*
  • Anti-Inflammatory Agents / pharmacology
  • Aorta / cytology
  • Aorta / metabolism
  • Cell Adhesion Molecules / genetics
  • Cell Adhesion Molecules / metabolism
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • Chemokines, CXC / genetics
  • Chemokines, CXC / metabolism
  • Chemotaxis, Leukocyte* / drug effects
  • Dose-Response Relationship, Drug
  • Estradiol / analogs & derivatives
  • Estradiol / metabolism*
  • Estradiol / pharmacology
  • Estrogen Antagonists / pharmacology
  • Estrogen Receptor beta / agonists
  • Estrogen Receptor beta / metabolism*
  • Estrogens / metabolism*
  • Estrogens / pharmacology
  • Female
  • Fulvestrant
  • Gene Expression / drug effects
  • HL-60 Cells
  • Humans
  • Inflammation / genetics
  • Inflammation / metabolism
  • Inflammation / prevention & control
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / metabolism
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / metabolism*
  • Neutrophils / drug effects
  • Neutrophils / metabolism*
  • Nitriles / pharmacology
  • RNA, Messenger / metabolism
  • Rats
  • Tumor Necrosis Factor-alpha / metabolism*

Substances

  • 2,3-bis(4-hydroxyphenyl)-propionitrile
  • Anti-Inflammatory Agents
  • Ccl2 protein, rat
  • Cell Adhesion Molecules
  • Chemokine CCL2
  • Chemokines, CXC
  • Cxcl3 protein, rat
  • Estrogen Antagonists
  • Estrogen Receptor beta
  • Estrogens
  • Nitriles
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Fulvestrant
  • Estradiol